AI systems could integrate blood glucose fluctuations with real-time retinal microvascular dynamics to predict the risk of vitreous hemorrhage and dynamically adjust anti-VEGF therapy regimens, thereby improving therapeutic response rates while reducing costs. This evidence concerns the gene VEGFA and vitreous hemorrhage.